Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide in HAM/TSP
NCT04799288Phase 2Recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Sep 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of teriflunomide in HTLV-1-associated myelopathy (HAM), sponsored by National Institute of Neurological Disorders and Stroke. Started Sep 2021; status: recruiting.
02
Drugs
teriflunomide
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on NCT04799288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799288.